SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2014 / Cilt: 5 - Sayı: 5

Küçük Hücreli Dışı Akciğer Kanseri Hastalarının Adjuvan Tedavisinde Sisplatin ve Etoposid

Cisplatin Plus Etoposide in the Adjuvant Treatment of Patients with Non-Small Cell Lung Cancer

Muharrem EROL
Erdem ÇUBUKÇU
Mustafa CANHOROZ
Ender KURT
Osman MANAVOĞLU
Turkkan EVRENSEL
Özkan KANAT
Sami BAYRAM
Ömer Fatih ÖLMEZ
Sinem ÇUBUKÇU
Nadide YORULMAZ
Pages
414–416
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Forty-five patients were evaluated.The disease-free survival was 10 (1-114) months and the median overallsurvival was 18 (3-114) months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE)combination in the adjuvant treatment of patients with resected non-smallcell lung cancer (NSCLC) was investigated.
📊
Key Findings & Data:Results: Forty-five patients were evaluated.The disease-free survival was 10 (1-114) months and the median overallsurvival was 18 (3-114) months.
💡
Conclusion & Impact:Discussion: Based on our limited experience,we concluded that PE regimen is safe and effective as adjuvant therapy forpatients with NSCLC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE)combination in the adjuvant treatment of patients with resected non-smallcell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated.The disease-free survival was 10 (1-114) months and the median overallsurvival was 18 (3-114) months. Discussion: Based on our limited experience,we concluded that PE regimen is safe and effective as adjuvant therapy forpatients with NSCLC.

Özet

Amaç: Bu çalışmada, opere edilmiş küçük hücreli dışı akciğer kanserli (KHDAK)hastaların adjuvan tedavisinde sisplatin ve etoposid (EP) kombinasyonun etkinliği ve güvenilirliği araştırıldı. Gereç ve Yöntem: Merkezimizde KHDAK tanısıyla adjuvan tedavi alan hastaların dosyaları retrospektif olarak değerlendirildi. Bulgular: 45 hasta değerlendirildi. Hastalıksız sağkalım süresi 10(1-114) ay ve ortalama genel sağkalım 18 ( 3-114) ay idi. Tartışma: Sınırlı deneyimimize dayanarak, KHDAK li hastalar için adjuvan tedavi olarak EP rejiminin etkin ve güvenilir olduğunu düşünüyoruz.

🔖

Cite This Article

EROL, M., ÇUBUKÇU, E., CANHOROZ, M., KURT, E., MANAVOĞLU, O., EVRENSEL, T., KANAT, Ö., BAYRAM, S., ÖLMEZ, Ö. F., ÇUBUKÇU, S., YORULMAZ, N. (2022). Küçük Hücreli Dışı Akciğer Kanseri Hastalarının Adjuvan Tedavisinde Sisplatin ve Etoposid. Journal of Clinical and Analytical Medicine, Cilt: 5 - Sayı: 5, 414–416. https://ajindex.com/articles/561187

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA Cancer J Clin 2006;56(2):106-30
  2. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I nonsmall cell lung cancer: A guide for future studies. J Clin Oncol 1984;2(12):1352-8
  3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111(6):1710-7
  4. Non small-cell Lung Cancer Collaborative Group: Chemotherapy in non-small- cell lung cancer: A meta-analysis using updated data on individial patients 52 randomized clinical trials. Br Med J 1995;311(7010):889-909
  5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non- small cell lung cancer. New Engl J Med 2004;350(4):351-60
  6. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067-77
  7. Sylvester R. WHO handbook for reporting results of cancer treatment. Control- led Clinical Trials 1980;1(3):276-77
  8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81
  9. Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB nonsmall cell lung cancer. Eur J Cardiothorac Surg 2001;20(2):378-84
  10. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non small cell lung cancer. J Natl Cancer Inst 2003;95(19):1453-61
  11. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: A randomized study on 70 patients. Chin Med J 2000;113(7):617-20
  12. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. Vinorelbine plus cisplatin vs. Observation in resected non-small cell lung cancer. Intergroup JBR
  13. N Engl J Med 2005;352(25):2589-97
  14. Tsuchiya R, K Suzuki, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa smal